Kura Oncology secures up to $150M in Bristol Myers equity investment, loan from Hercules Capital
Kura Oncology is set for a few more years, thanks to some new partners.
The public oncology biotech put out word last week that it brought in some more funding — which, if maxed out, will extend its runway into 2026. The first amount of financing is from Bristol Myers, which is investing $25 million into the biotech as an equity investment. The second, more substantial financing is in the form of a term loan facility worth $125 million from Hercules Capital.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.